Pharmexa sells Pharmexa-Epimmune to VaxOnco in South Korea

Published: 28-May-2009
Media Pharmaceutical

VaxOnco, a South Korean company specialising in peptide based vaccines, has acquired Pharmexa-Epimmune from Danish company Pharmexa for Euro 440,000. VaxOnco will thus assume all rights and responsibilities relating to the Pharmexa-Epimmune patent portfolio.


VaxOnco, a South Korean company specialising in peptide based vaccines, has acquired Pharmexa-Epimmune from Danish company Pharmexa for Euro 440,000. VaxOnco will thus assume all rights and responsibilities relating to the Pharmexa-Epimmune patent portfolio.

Dr Achim Kaufhold, Pharmexa's ceo, said: "In line with our cost-cutting activities and our new strategic direction, Pharmexa discontinued operations at our Pharmexa-Epimmune subsidiary in San Diego at the end of last year. The sale of Pharmexa-Epimmune to VaxOnco completes that process and will result in substantial savings to Pharmexa in the future."

See more

You may also like

Packaging

ProMach Pharma presents new equipment at Pack Expo Las Vegas

Read more
Several new systems will be on exhibit for the first time, alongside other advanced processing and packaging equipment for pharmaceuticals, biopharmaceuticals, nutraceuticals, medical devices and more

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. ProMach Pharma presents new equipment at Pack Expo Las Vegas Several new systems will be on exhibit for the first time, alongside other advanced processing and packaging equipment for pharmaceuticals, biopharmaceuticals, nutraceuticals, medical devices and more
  3. Bavarian Nordic launches chikungunya vaccine Vimkunya in the UK The UK announcement of the recombinant vaccine follows recent approval by the MHRA in May 2025
  4. CPHI Frankfurt 2025 to welcome more than 60,000 pharma professionals with expanded focus on innovation and sustainability Returning to Germany from 28-30 October, CPHI Frankfurt 2025 will unite the global pharmaceutical supply chain with more than 2000 exhibitors, six content theatres and new feature zones
  5. Can Aztekin receives Rising Star Award 2025 from the International Society of Regenerative Biology

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Packaging

ProMach Pharma presents new equipment at Pack Expo Las Vegas

Several new systems will be on exhibit for the first time, alongside other advanced processing and packaging equipment for pharmaceuticals, biopharmaceuticals, nutraceuticals, medical devices and more
Pharmaceutical

CPHI Frankfurt 2025 to welcome more than 60,000 pharma professionals with expanded focus on innovation and sustainability

Returning to Germany from 28-30 October, CPHI Frankfurt 2025 will unite the global pharmaceutical supply chain with more than 2000 exhibitors, six content theatres and new feature zones
Manufacturing

Continuous innovation: redefining the future of pharmaceutical manufacturing

In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
Pharmaceutical

Keystone Folding Box Co. unveils Key-Pak Plus

Designed to protect children and empower seniors, it achieves top U.S. safety ratings and meets global accessibility standards
Pharmaceutical

Bavarian Nordic launches chikungunya vaccine Vimkunya in the UK

The UK announcement of the recombinant vaccine follows recent approval by the MHRA in May 2025
Research & Development

Servier and IDEAYA Biosciences join forces to bring a promising new eye cancer treatment to patients across the globe

Servier and IDEAYA Biosciences have entered into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the US
Pharmaceutical

Atelerix and Rodon Global enter new partnership to create cryo-free logistics

The initial agreement will be to incorporate Atelerix’s non-cryogenic cell preservation technology into Rodon's international freight and logistics services for drug discovery and clinical trials
Subscribe now